Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 8 | 119,192 | $29.19M |
| Grant or award | 4 | 686 | |
| Option exercise | 2 | 312,412 | |
| Derivative transaction | 2 | 49,927 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
69 Form 4 filings on record, the earliest from Nov 8, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| W. Richard Staub - Officer | Open-market sale | Common Stock | 5,500 | $232.68 | $1.28M | |
| Open-market sale | Common Stock | 1,855 | $235.27 | $436K | ||
| Open-market sale | Common Stock | 5,000 | $249.16 | $1.25M | ||
| Open-market sale | Common Stock | 558 | $245.21 | $137K | ||
| Ari Bousbib - Officer | Option exercise | Common Stock | 156,206 | $78.21 | $12.22M | |
| Ari Bousbib - Officer | Open-market sale | Common Stock | 4,465 | $247.10 | $1.10M | |
| Ari Bousbib - Officer | Open-market sale | Common Stock | 4,584 | $246.85 | $1.13M | |
| Ari Bousbib - Officer | Open-market sale | Common Stock | 44,039 | $246.08 | $10.84M | |
| Ari Bousbib - Officer | Open-market sale | Common Stock | 53,191 | $244.78 | $13.02M | |
| Ari Bousbib - Officer | Derivative | Common Stock | 47,858 | $244.60 | $11.71M | |
| Ari Bousbib - Officer | Derivative | Common Stock | 2,069 | $247.00 | $511K | |
| Ari Bousbib - Officer | Option exercise | Stock Appreciation Right | 156,206 | $78.21 | $12.22M | |
| Grant or award | Deferred Shares | 148 | $207.83 | $31K | ||
| Grant or award | Deferred Shares | 183 | $207.83 | $38K | ||
| Jim Fasano - Director | Grant or award | Deferred Shares | 195 | $207.83 | $41K | |
| Grant or award | Deferred Shares | 160 | $207.83 | $33K | ||
| Grant or award | Deferred Shares | 171 | $178.64 | $31K | ||
| Grant or award | Deferred Shares | 214 | $178.64 | $38K | ||
| Jim Fasano - Director | Grant or award | Deferred Shares | 228 | $178.64 | $41K | |
| Grant or award | Deferred Shares | 185 | $178.64 | $33K | ||
| Sheila A. Stamps - Director | Grant or award | Deferred Shares | 1,571 | $160.68 | $252K | |
| Grant or award | Deferred Shares | 1,571 | $160.68 | $252K | ||
| William G. Kaelin Jr. - Director | Grant or award | Deferred Shares | 1,571 | $160.68 | $252K | |
| John M. Leonard - Director | Grant or award | Common Stock | 1,571 | $0.00 | - | |
| Grant or award | Common Stock | 1,571 | $0.00 | - | ||
| Jim Fasano - Director | Grant or award | Deferred Shares | 1,571 | $160.68 | $252K | |
| Grant or award | Common Stock | 1,571 | $0.00 | - | ||
| Carol Burt - Director | Grant or award | Common Stock | 1,571 | $0.00 | - | |
| Bernd Haas - Officer | Tax withholding / forfeiture | Common Stock | 20 | $166.94 | $3K | |
| Michael J. Fedock - Officer | Tax withholding / forfeiture | Common Stock | 123 | $166.94 | $21K | |
| W. Richard Staub - Officer | Grant or award | Stock Appreciation Right | 26,088 | $0.00 | - | |
| Grant or award | Stock Appreciation Right | 12,112 | $0.00 | - | ||
| Grant or award | Stock Appreciation Right | 11,180 | $0.00 | - | ||
| Bernd Haas - Officer | Grant or award | Stock Appreciation Right | 11,180 | $0.00 | - | |
| Alistair Grenfell - Officer | Grant or award | Stock Appreciation Right | 26,088 | $0.00 | - | |
| Michael J. Fedock - Officer | Grant or award | Stock Appreciation Right | 18,634 | $0.00 | - | |
| Grant or award | Stock Appreciation Right | 2,795 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| WALTER STAUB | Officer | 5,500 | $1.28M | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
IQVIA HOLDINGS INC. (IQV) had 9 insider filings in the last 90 days, with the most recent on 2026-08-04. The full record for IQV runs to 69 Form 4 filings, the earliest from 2024-11-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IQV were filed in the last 90 days.
8 insider sales of IQV were filed in the last 90 days, totaling $29.19M.
This page tracks IQV Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IQV to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.